GLP-1 Receptor Agonists Market (2026-2036)
The global GLP-1 Receptor Agonists Market was valued at USD 78.4 billion in 2025. This market is expected to reach USD 200.3 billion by 2036 from an estimated USD 88.6 billion in 2026, registering a CAGR of 8.5% during the forecast period (2026-2036).
- Published
- Oct 2026
- Pages
- 308
- Format
- PDF + Excel
- Report ID
- MR-2267
- Base year
- 2025
- 2025 · BASELINE
- $78.40B
- 2036
- $200.3B
- CAGR 2026–2036
- 8.5%
2025 baseline · 2026–2036 forecast at 8.5% CAGR · hover a bar for the value
Key highlights
The global GLP-1 Receptor Agonists Market is projected to reach USD 200.3 billion by 2036, driven by obesity and diabetes prevalence, new indications, and oral and next-generation agonists.
North America is expected to account for the largest market share in 2026, while Asia-Pacific is projected to register the fastest growth during the forecast period.
Tirzepatide became the world's best-selling drug. Eli Lilly reported 2025 revenue of USD 22.97 billion for Mounjaro, up 99%, and USD 13.54 billion for Zepbound, up 175%, a combined USD 36.5 billion, and guided 2026 company revenue of USD 80 billion to USD 83 billion.
By molecule, Tirzepatide is expected to account for the largest market share, whereas next-generation agonists are projected to witness the fastest growth through 2036.
Prices are falling as volumes grow. Lilly reported a 5% decline in realized prices in the fourth quarter of 2025, partly due to its agreement with the U.S. government, and Novo Nordisk guided in February 2026 to a 5% to 13% decline in adjusted sales at constant exchange rates, citing lower U.S. prices and the patent expiry of semaglutide in certain international markets.
Oral GLP-1 therapies are entering the obesity market. The U.S. FDA approved once-daily oral semaglutide 25 mg as the Wegovy pill on 22 December 2025, the first oral GLP-1 for obesity; it launched on 5 January 2026 and reached around 50,000 weekly prescriptions by 23 January.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026-2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 8.5% |
| Format | PDF, Excel & Cloud Portal · 308 pages |
| Market Size (Value) in 2026 | USD 88.6 Billion |
| Market Size (Value) in 2036 | USD 200.3 Billion |
| Segments Covered | By Molecule: Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide & Others, Next-Generation Agonists. By Mechanism: Mono GLP-1 Agonists, Dual Agonists, Triple Agonists. By Route of Administration: Injectable, Oral. By Indication: Type 2 Diabetes, Obesity & Overweight, Cardiovascular Risk Reduction, Chronic Kidney Disease, Obstructive Sleep Apnea, MASH, Others. By Product Type: Branded, Generic. By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online & Direct-to-Consumer. By Payer Channel: Commercial Insurance, Public Payers, Self-Pay. |
| Countries Covered | North America: U.S., Canada. Europe: Germany, U.K., France, Italy, Spain, Denmark & Nordic Countries, Rest of Europe. Asia-Pacific: China, Japan, India, South Korea, Australia, Rest of Asia-Pacific. Latin America: Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America. Middle East & Africa: Saudi Arabia, UAE, Kuwait & Qatar, Türkiye, Egypt, South Africa, Rest of Middle East & Africa. |
| Key Companies | Novo Nordisk, Eli Lilly, Amgen, Pfizer, Roche, AstraZeneca, Boehringer Ingelheim, Zealand Pharma, Viking Therapeutics, Structure Therapeutics, Innovent Biologics, Jiangsu Hengrui, Hangzhou Jiuyuan, Huadong Medicine, Hanmi Pharmaceutical, Dr. Reddy's, Biocon, Sun Pharma, Sandoz, and Teva. |
Report overview
Segments covered: molecule, mechanism, route of administration, indication, product type, distribution channel, payer channel.
The growth of this market is mainly driven by the global rise in obesity and type 2 diabetes, the expansion of GLP-1 therapies into cardiovascular, kidney, sleep apnea, and liver indications, and the arrival of oral and next-generation agonists. However, pricing pressure from government agreements and list price cuts, the loss of exclusivity for semaglutide in major international markets, poor long-term persistence with treatment, and emerging safety signals restrain the growth of this market.
Furthermore, generic and lower-cost GLP-1s in emerging markets, direct-to-consumer and self-pay channels, and multi-agonist combinations are expected to offer growth opportunities for the stakeholders in this market. However, competition from compounded and counterfeit products, limited payer coverage for obesity, manufacturing capacity constraints, and clinical differentiation and pipeline risk remain major challenges impacting the growth of this market. Additionally, the shift to oral GLP-1s, falling prices with expanding volumes, the move to higher doses and multi-agonists, and rising dealmaking for next-generation assets are prominent trends in this market.
The GLP-1 Receptor Agonists Market comprises drugs that activate the glucagon-like peptide-1 receptor to lower blood glucose, reduce appetite, and promote weight loss, including multi-receptor agonists that combine GLP-1 activity with GIP, glucagon, or amylin pathways. The market covers marketed mono-agonists such as semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide; the dual GIP and GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound); oral formulations including oral semaglutide and small-molecule agonists; next-generation agonists in late-stage development; and generic and biosimilar versions as patents expire. Indications include type 2 diabetes, chronic weight management, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis (MASH). The ecosystem spans originator pharmaceutical companies, biotechnology developers, generic manufacturers, contract manufacturers, pharmacies and direct-to-consumer platforms, payers, and prescribers.
The GLP-1 class has become the largest therapeutic category in the pharmaceutical industry. Eli Lilly reported that Mounjaro generated USD 22.97 billion and Zepbound USD 13.54 billion in 2025, making tirzepatide the world's best-selling medicine, with fourth-quarter company revenue up 43% to USD 19.3 billion and 2026 revenue guidance of USD 80 billion to USD 83 billion. Novo Nordisk reported 2025 sales of obesity care products, mainly Wegovy, of DKK 82.3 billion, up from DKK 65.1 billion in 2024, alongside large Ozempic diabetes sales. The World Health Organization estimated that in 2022 one in eight people worldwide was living with obesity, and in December 2025 issued its first guideline conditionally recommending GLP-1 therapies for obesity.
The market is entering a phase of rapidly expanding volume and falling prices. Under agreements with the U.S. administration announced in November 2025, Medicare is expected to cover Ozempic and Wegovy at USD 245 per month from mid-2026 with a USD 50 co-pay, and Novo Nordisk announced that from 1 January 2027 it will cut the U.S. list price of Wegovy and Ozempic to USD 675, reductions of about 50% and 35%. Lilly reported a 5% decline in realized prices in the fourth quarter of 2025, and Novo Nordisk guided in February 2026 to a 5% to 13% decline in 2026 adjusted sales at constant exchange rates, later improved to 0% to minus 6%. The compound patent for semaglutide expires in 2026 in several international markets, opening the way for generics, while Novo Nordisk's liraglutide has already lost patent protection worldwide.
Innovation continues at pace. The FDA approved the Wegovy pill, oral semaglutide 25 mg, on 22 December 2025 as the first oral GLP-1 for obesity; it launched on 5 January 2026. Lilly submitted its oral small-molecule agonist orforglipron for obesity in the U.S. and Japan and for obesity and type 2 diabetes in the EU by early 2026. Novo Nordisk has submitted a higher 7.2 mg dose of Wegovy and its combination CagriSema to the FDA, and developers including Amgen, Boehringer Ingelheim, Roche, AstraZeneca, and Pfizer are advancing next-generation agonists.
Market dynamics
18 factors across 5 forcesGlobal Rise in Obesity and Type 2 Diabetes
The global rise in obesity and type 2 diabetes is a major factor driving the GLP-1 Receptor Agonists Market. The World Health Organization estimated that in 2022 one in eight people in the world was living with obesity, with 2.5 billion adults overweight, including 890 million living with obesity, and that adult obesity worldwide had more than doubled since 1990. In December 2025, the WHO issued its first guideline on GLP-1 therapies for obesity, conditionally recommending their use for adults with obesity. Demand is reflected in sales: Lilly's tirzepatide franchise generated USD 36.5 billion in 2025, and Novo Nordisk's obesity care sales rose to DKK 82.3 billion from DKK 65.1 billion in 2024.
Expansion into New Indications
The expansion of GLP-1 therapies into new indications is significantly broadening the treatable population. The FDA approved Wegovy in March 2024 to reduce the risk of major cardiovascular events after the SELECT trial showed a 20% reduction in risk, approved Ozempic in January 2025 to reduce kidney disease progression and cardiovascular death in patients with type 2 diabetes and chronic kidney disease, approved Zepbound in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity, and granted accelerated approval to Wegovy in August 2025 for MASH with moderate to advanced liver fibrosis. Each new indication strengthens the clinical and economic case for treatment and supports payer coverage.
Arrival of Oral and Next-Generation Agonists
The arrival of oral and next-generation agonists is expanding patient choice and reach. The FDA approved the Wegovy pill on 22 December 2025, and after its launch on 5 January 2026, weekly prescriptions reached around 50,000 by 23 January, driven mainly by the starter dose in the self-pay channel. Lilly submitted orforglipron, an oral small-molecule GLP-1 that does not require the food and water restrictions of oral peptides and can be manufactured more easily at scale, for regulatory approval in the U.S., Japan, and the EU. Novo Nordisk has submitted Wegovy 7.2 mg and CagriSema to the FDA, and multiple companies are developing triple agonists and amylin combinations for greater weight loss.
Table of contents
15 chapters · 192 sections · 308 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Molecule | Tirzepatide | Next-Generation Agonists |
| By Mechanism | Mono GLP-1 Agonists | Triple Agonists |
| By Route of Administration | — | Rapid growth of this |
| By Indication | Type 2 Diabetes | Obesity & Overweight |
| By Product Type | — | Rapid growth of this |
| By Distribution Channel | Retail Pharmacies | Online & Direct-to-Consumer |
| By Payer Channel | Commercial Insurance | Self-Pay |
By Molecule
- The Tirzepatide segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to superior weight loss and rapid global expansion of Mounjaro and Zepbound.
- However, the Next-Generation Agonists segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to launches of oral small molecules, amylin combinations, and triple agonists.
By Mechanism
- The Mono GLP-1 Agonists segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the broad installed base of semaglutide, liraglutide, and dulaglutide across diabetes and obesity, together with the entry of lower-cost generics in international markets.
- However, the Triple Agonists segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to the greater weight loss targeted by candidates such as retatrutide and their expected launch in the latter half of the forecast period.
By Route of Administration
- Market Analysis by Route of Administration
- The Injectable segment is expected to account for the larger share of the market.
- The large share of this segment is mainly due to the dominance of once-weekly injectables such as Mounjaro, Zepbound, Ozempic, and Wegovy across both diabetes and obesity.
- However, the Oral segment is projected to register the higher CAGR during the forecast period.
- The rapid growth of this segment is attributed to the launch of the Wegovy pill in January 2026, the anticipated approval of orforglipron, and patient preference for needle-free treatment.
By Indication
- The Type 2 Diabetes segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to established treatment guidelines, broad reimbursement, and the large installed base of Mounjaro, Ozempic, Trulicity, and Rybelsus.
- However, the Obesity & Overweight segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to rising obesity prevalence, the WHO's December 2025 guideline recommending GLP-1 therapies for obesity, expanding Medicare access from mid-2026, and the arrival of oral options.
By Product Type
- The Branded segment is expected to account for the larger share of the market.
- The large share of this segment is mainly due to continued patent protection for tirzepatide and for semaglutide in the U.S. and Europe.
- However, the Generic segment is projected to register the higher CAGR during the forecast period.
- The rapid growth of this segment is attributed to the expiry of semaglutide's compound patent in several international markets from 2026 and the availability of generic liraglutide worldwide.
By Distribution Channel
- The Retail Pharmacies segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the chronic, outpatient nature of GLP-1 therapy and the dispensing of insured prescriptions through retail networks.
- However, the Online & Direct-to-Consumer segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to manufacturer platforms such as LillyDirect and NovoCare, telehealth prescribing, and the self-pay uptake of the Wegovy pill.
By Payer Channel
- The Commercial Insurance segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to employer and health plan coverage for type 2 diabetes and, increasingly, obesity.
- However, the Self-Pay segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to falling cash prices, including initiation prices as low as USD 199, and persistent gaps in insurance coverage for obesity.
Geographic analysis
North America
Largest shareIn 2026, North America is expected to account for the largest share of the global GLP-1 Receptor Agonists Market. The region's dominance is supported by high obesity and diabetes prevalence, strong commercial insurance coverage, and early access to new therapies. In the U.S., Lilly's Mounjaro sales rose 57% to USD 4.1 billion in the fourth quarter of 2025, and Zepbound, sold mainly in the U.S., reached USD 13.54 billion in 2025. The November 2025 agreements with the U.S. administration provide Medicare access to Ozempic and Wegovy at USD 245 per month from mid-2026, and Novo Nordisk will cut U.S. list prices to USD 675 from January 2027, while compounded products continued to compete after the FDA's grace period ended on 22 May 2025. In Canada, the semaglutide compound patent expired in 2026, and Novo Nordisk cited Canada among markets where loss of exclusivity would affect its outlook. Mexico, where adult obesity affects more than a third of the population, and Brazil, Argentina, Colombia, and Chile have large self-pay markets for GLP-1 therapies. North America
Europe
Europe is expected to account for a significant share of the market and is home to Novo Nordisk, headquartered in Denmark. Novo Nordisk's Region EUCAN sales grew 23% at constant exchange rates in the first quarter of 2026, and the European Medicines Agency concluded in June 2025 that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 people. Reimbursement varies widely: the U.K.'s National Health Service began offering Mounjaro through general practitioners in June 2025, while Germany's statutory health insurance does not reimburse medicines for weight loss. Lilly submitted orforglipron for obesity and type 2 diabetes in the EU, and France, Italy, Spain, and the Nordic countries are expanding access. Europe
Asia-Pacific
Fastest growthHowever, Asia-Pacific is projected to register the highest CAGR during the forecast period. The rapid growth of this region is attributed to its large populations with diabetes and rising obesity, expanding reimbursement, and the entry of lower-cost generics and domestic innovators. Novo Nordisk's Region APAC sales grew 22% at constant exchange rates in the first quarter of 2026, while sales in China fell 10% amid lower realized prices. In China, the semaglutide compound patent was upheld by the Supreme People's Court in December 2025 ahead of its expiry in 2026, a biosimilar liraglutide was approved in 2023, and domestic developers such as Innovent, whose dual agonist mazdutide was approved in China in 2025, are competing. India's semaglutide patent expiry in 2026 is expected to bring low-cost generics, and Japan approved Wegovy for obesity in 2023, launching it in 2024. Lilly submitted orforglipron for obesity in Japan. Asia-Pacific
Latin America
Latin America is expected to account for a moderate share of the market, with high obesity prevalence and price sensitivity. Novo Nordisk's sales in its Emerging Markets region, which includes Latin America, fell 18% at constant exchange rates in the first quarter of 2026 amid competition and pricing pressure, and the expiry of semaglutide's patent in Brazil in 2026 is expected to bring generic competition from local manufacturers. Latin America
Middle East & Africa
The Middle East & Africa is expected to register strong growth from a smaller base. Gulf countries, including Saudi Arabia, the UAE, Kuwait, and Qatar, have among the world's highest rates of obesity and diabetes and strong demand for GLP-1 therapies, including through private and self-pay channels. Novo Nordisk's Emerging Markets region, which includes the Middle East and Africa, recorded an 18% sales decline at constant exchange rates in the first quarter of 2026, reflecting competition and pricing, while South Africa, Egypt, and Türkiye are expected to benefit from lower-cost generics as semaglutide exclusivity erodes in international markets. The International Diabetes Federation estimated that about 73 million adults in the Middle East and North Africa were living with diabetes in 2021, one of the highest regional prevalence rates in the world, and WHO data show adult obesity rates approaching or exceeding 35% in several Gulf states, including Kuwait and Qatar. Middle East & Africa
Competitive landscape
The global GLP-1 Receptor Agonists Market is highly concentrated, with Eli Lilly and Novo Nordisk accounting for the great majority of sales, followed by a large pipeline of biotechnology and pharmaceutical challengers, fast-growing Chinese developers, and generic manufacturers preparing for semaglutide loss of exclusivity. Competition centers on efficacy, tolerability, convenience of dosing and administration, breadth of indications, manufacturing capacity, pricing, and access through payers and direct-to-consumer channels.
Leading companies are launching oral formulations, pursuing higher doses and multi-agonist combinations, expanding manufacturing capacity, cutting prices and building direct-to-consumer channels, and acquiring or licensing next-generation assets. Pfizer's acquisition of Metsera in November 2025 after a competitive bidding contest with Novo Nordisk illustrates the value placed on pipeline assets.
The report provides a comprehensive competitive assessment of the leading companies operating in the global GLP-1 Receptor Agonists Market. The key players profiled in the report include Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca PLC (U.K.), Boehringer Ingelheim International GmbH (Germany), Zealand Pharma A/S (Denmark), Viking Therapeutics, Inc. (U.S.), Structure Therapeutics Inc. (U.S.), Innovent Biologics, Inc. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), Hangzhou Jiuyuan Gene Engineering Co., Ltd. (China), Huadong Medicine Co., Ltd. (China), Hanmi Pharmaceutical Co., Ltd. (South Korea), Dr. Reddy's Laboratories Ltd. (India), Biocon Limited (India), Sun Pharmaceutical Industries Ltd. (India), Sandoz Group AG (Switzerland), and Teva Pharmaceutical Industries Ltd. (Israel).
- Novo Nordisk
- Eli Lilly
- Amgen
- Pfizer
- Roche
- AstraZeneca
- Boehringer Ingelheim
- Zealand Pharma
- Viking Therapeutics
- Structure Therapeutics
- Innovent Biologics
- Jiangsu Hengrui
- Hangzhou Jiuyuan
- Huadong Medicine
- Hanmi Pharmaceutical
- Dr. Reddy's
- Biocon
- Sun Pharma
- Sandoz
- Teva
Expert perspectives
GLP-1 receptor agonists have become the largest drug class in the world, with tirzepatide alone generating USD 36.5 billion in 2025. The market is now entering a new phase in which volumes will keep growing rapidly while prices fall sharply, as shown by Lilly's 5% price decline in late 2025, the U.S. government agreements, Novo Nordisk's planned list price cuts of up to 50%, and semaglutide generics in international markets from 2026.
Three structural changes are expected to shape the market through 2036. First, oral and small-molecule agonists will broaden access and ease manufacturing constraints. Second, the market will split between premium, highly effective multi-agonists and lower-cost generic and oral options, particularly in emerging markets. Third, persistence, payer coverage, and outcomes data across cardiovascular, kidney, liver, and sleep indications will determine long-term value as health systems weigh budgets against health benefits.
For companies planning entry or expansion, the most attractive positions over the forecast period are likely to be found in oral and next-generation multi-agonists, generic semaglutide and liraglutide in emerging markets, direct-to-consumer channels, and manufacturing and fill-finish capacity. The principal risks are price erosion, generic competition, poor persistence, safety signals, and compounded and counterfeit supply.
Customer perspectives
Insights gathered during primary interviews with endocrinologists, obesity medicine specialists, payers, and pharmacy executives highlight where purchasing priorities are shifting. The following perspectives reflect recurring themes raised across these discussions.
“This reflects the importance of persistence, tolerability, and convenience in clinical decision-making.”
“This indicates that price and outcomes evidence drive payer coverage of GLP-1s for obesity.”
“This points to large volume opportunities for generics in emerging markets and the importance of manufacturing scale.”
Frequently asked questions
The global GLP-1 Receptor Agonists Market is estimated at USD 88.6 billion in 2026.
Cite this report
Meticulous Research. (2026). GLP-1 Receptor Agonists Market - Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2267). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/glp-1-receptor-agonists-market-6950